Patents by Inventor Curtis Wright

Curtis Wright has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OXYCODONE FORMULATIONS
    Publication number: 20170340626
    Abstract: The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C24/Cmax oxycodone ratio of 0.6 to 1.0 or 0.
    Type: Application
    Filed: August 1, 2017
    Publication date: November 30, 2017
    Inventors: Benjamin OSHLACK, Curtis WRIGHT, Derek PRATER
  • Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
    Patent number: 9808453
    Abstract: Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: November 7, 2017
    Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Benjamin Oshlack, Curtis Wright, Christopher Breder
  • Tamper resistant oral opioid agonist formulations
    Patent number: 9801828
    Abstract: Oral dosage forms containing an opioid antagonist in a sequestered form are described. The opioid antagonist is sequestered such that it is not released or substantially not released in the gastrointestinal tract from the dosage form which is administered orally intact. However, when the dosage form is chewed, crushed, heated or dissolved in a solvent, and then administered orally, intranasally, parenterally or sublingually, the opioid antagonist is released and at least partially blocks effects of the opioid agonist.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: October 31, 2017
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Curtis Wright, J. David Haddox
  • Pharmaceutical Formulation Containing Gelling Agent
    Publication number: 20170296533
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Application
    Filed: June 29, 2017
    Publication date: October 19, 2017
    Applicants: The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Pharmaceutical formulation containing gelling agent
    Patent number: 9757341
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: September 12, 2017
    Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Oxycodone formulations
    Patent number: 9750736
    Abstract: The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C24/Cmax oxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: September 5, 2017
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Curtis Wright, Derek Prater
  • Acetaminophen-Containing Analgesic Formulations With Reduced Hepatotoxicity
    Publication number: 20170246194
    Abstract: An analgesic composition is provided which is safe and effective to patients requiring pain modulation. The analgesic composition contains (a) acetaminophen and (b) at least three components chosen from (i) a bioavailable oral opioid; (ii) a non-steroidal anti-inflammatory drug; (iii) a sulfur-containing, N-acetyl-p-benzoquinone imine scavenging agent or prodrug thereof; or (iv) an agent which lowers acetaminophen toxicity. These analgesic compositions inhibit the formation or reduce the presence of NAPQI, the toxic acetaminophen by-product responsible for liver toxicity in patients. These analgesic compositions are also safely tolerated by patients administering more than the maximum dosage of acetaminophen.
    Type: Application
    Filed: August 14, 2015
    Publication date: August 31, 2017
    Applicant: Purdue Pharma L.P.
    Inventor: Curtis WRIGHT, IV
  • Pharmaceutical formulation containing gelling agent
    Patent number: 9693961
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: July 4, 2017
    Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • PHARMACEUTICAL FORMULATION CONTAINING OPIOID AGONIST, OPIOID ANTAGONIST AND GELLING AGENT
    Publication number: 20170157115
    Abstract: Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid.
    Type: Application
    Filed: December 19, 2016
    Publication date: June 8, 2017
    Inventors: Benjamin Oshlack, Curtis Wright, Christopher Breder
  • Once-a-day oxycodone formulations
    Patent number: 9655893
    Abstract: The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C24/Cmax oxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: May 23, 2017
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Curtis Wright, Derek Prater
  • Once-A day oxycodone formulations
    Patent number: 9655894
    Abstract: The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C24/Cmax oxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: May 23, 2017
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Curtis Wright, Derek Prater
  • TAMPER RESISTANT ORAL OPIOID AGONIST FORMULATIONS
    Publication number: 20170119685
    Abstract: Oral dosage forms containing an opioid antagonist in a sequestered form are described. The opioid antagonist is sequestered such that it is not released or substantially not released in the gastrointestinal tract from the dosage form which is administered orally intact. However, when the dosage form is chewed, crushed, heated or dissolved in a solvent, and then administered orally, intranasally, parenterally or sublingually, the opioid antagonist is released and at least partially blocks effects of the opioid agonist.
    Type: Application
    Filed: August 24, 2016
    Publication date: May 4, 2017
    Inventors: Benjamin Oshlack, Curtis Wright, J. David Haddox
  • Pharmaceutical Formulation Containing Gelling Agent
    Publication number: 20170112765
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Application
    Filed: November 8, 2016
    Publication date: April 27, 2017
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Pharmaceutical Formulation Containing Gelling Agent
    Publication number: 20170065525
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Application
    Filed: November 17, 2016
    Publication date: March 9, 2017
    Applicants: The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Pharmaceutical Formulation Containing Gelling Agent
    Publication number: 20170065524
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Application
    Filed: November 17, 2016
    Publication date: March 9, 2017
    Applicants: The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
    Patent number: 9561225
    Abstract: Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: February 7, 2017
    Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Benjamin Oshlack, Curtis Wright, Christopher Breder
  • Pharmaceutical Formulation Containing Gelling Agent
    Publication number: 20170020864
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Application
    Filed: October 4, 2016
    Publication date: January 26, 2017
    Applicants: The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Pharmaceutical Formulation Containing Gelling Agent
    Publication number: 20170020863
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Application
    Filed: October 4, 2016
    Publication date: January 26, 2017
    Applicants: The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Pharmaceutical formulation containing gelling agent
    Patent number: 9522115
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: December 20, 2016
    Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Pharmaceutical formulation containing gelling agent
    Patent number: 9517206
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: December 13, 2016
    Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder